Glaxosmithkline Share News (GSK)

Britain's Cameron defends GSK's business practices in China

By Andrew Osborn and Ben Hirschler SHANGHAI, Dec 3 (Reuters) - British Prime Minister David Cameron on Tuesday mounted a robust defence of GlaxoSmithKline's business practices in China - where it is being investigated for alleged bribery - calling the firm "very decent". Cameron's in

UPDATE 2-OncoMed stock doubles after cancer drug deal with Celgene

* OncoMed to get upfront payments of $177.25 mln * Celgene to take 5 pct stake in OncoMed * Celgene stock down 1.4 pct (Adds CEO, analyst comments, details on deal; updates share price) Dec 3 (Reuters) - Shares of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after

Drug companies still struggling to improve R&D returns

* R&D returns at top 12 drug firms continue to slide * Average return 4.8 pct in 2013 vs 10.5 pct in 2010 * Average new drug cost $1.3 bln - Deloitte, Thomson Reuters By Ben Hirschler LONDON, Dec 3 (Reuters) - The number of new drugs approved for sale by regulators may be

UPDATE 4-UK's Cameron clashes with Brussels over EU-China trade

* Cameron in first China trip since Dalai Lama row last year * British PM's priority is to deepen economic ties * Cameron pushes EU-China trade agreement * EU executive says such talks are premature By Andrew Osborn and Ben Blanchard BEIJING, Dec 2 (Reuters) - Britis

UPDATE 1-Cameron raises GSK's problems as CEO joins him on China visit

* PM stresses need for stable business environment -source * Witty on first visit to China since bribery scandal * CEO expects update on graft investigation "quite soon" * GSK spokesman says trade trip shows commitment to China By Andrew Osborn and Ben Hirschler BEIJ

GSK says CEO's China visit flags commitment in face of graft scandal

* Witty on first visit to China since bribery scandal * CEO expects update on graft investigation "quite soon" * GSK spokesman says trade trip shows commitment to China LONDON/BEIJING, Dec 2 (Reuters) - GlaxoSmithKline's (GSK) chief executive is showing his commitment to doing

Britain's Cameron flies to Beijing, pushing EU-China trade deal

* Cameron in first China trip since Dalai Lama row last year * Priority is to deepen economic ties * Cameron says he will push EU-China trade deal * Campaigners urge him to raise Tibet By Andrew Osborn BEIJING, Dec 2 (Reuters) - British Prime Minister David Cameron f

Britain's Cameron "turns page" on Dalai Lama row with China visit

* Cameron in first China trip since Dalai Lama row last year * Priority is to deepen economic ties * Campaigners urge him to raise Tibet By Andrew Osborn LONDON, Nov 30 (Reuters) - Britain has put a diplomatic rift with China over the Dalai Lama behind it and Prime Ministe

GlaxoSmithKline Cervical Cancer Vaccine Variant Recommended For EU Approval

EU mergers and takeovers (Nov 28)

BRUSSELS, Nov 28 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process: APPROVALS AND WITHDRAWALS -- Japan's Suntory Beverage & Food Ltd to buy British drugmaker GlaxoSmithKline Plc's Lucozade and Ribena brands (approv

Galapagos: GSK2586184 JAK1 Molecule Moves Into Phase 2 For Ulcerative Colitis

STOCKS NEWS EUROPE-Europe equities to rise 14 pct next yr-Nomura

Earnings growth will help European equity markets gain 14 percent next year, while a falling risk premium and flows back into the asset class are likely to support the market in the longer term, Nomura says, echoing similarly bullish comments from Goldman Sachs and UBS last week. "The rally

UPDATE 1-US FDA lifts restrictions on Glaxo diabetes drug Avandia

By Bill Berkrot and Ransdell Pierson Nov 25 (Reuters) - U.S. health regulators said on Monday they would lift restrictions on the use of GlaxoSmithKline Plc's once widely prescribed diabetes drug Avandia, after determining that it did not increase the risk of heart attacks. The U.S.

US FDA lifts restrictions on Glaxo diabetes drug Avandia

Nov 25 (Reuters) - U.S. health regulators on Monday said they would lift restrictions on the use of GlaxoSmithKline Plc's once widely used diabetes drug Avandia after determining that it did not increase the risk of heart attacks. The U.S. Food and Drug Administration, following its review

DIRECTOR DEALINGS: GlaxoSmithKline Director Awarded ADSs